Ewing sarcoma is the second most common primary bone tumour in paediatric population, accounting for about 1% of all childhood cancers. This malignancy typically originates in the bones or the surrounding soft tissues and most frequently affects AYAs, with a common age range at diagnosis between 10 and 20 years. The incidence of Ewing sarcoma is notably higher among individuals of European and North African/Middle Eastern ancestry, making it a significant concern in these populations. Despite its rarity, Ewing sarcoma is known for its aggressive nature and the challenges it presents in treatment and management. ⁽²⁾⁽³⁾